Exp Clin Endocrinol Diabetes 1999; 107(1): 35-39
DOI: 10.1055/s-0029-1212070
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Enhanced erythrocyte aggregation in type 2 diabetes with late complications

H. Demiroğlu1 , A. Gürlek2 , I. Barişta3
  • 1Department of Hematology, Hacettepe University School of Medicine, Ankara, Turkey
  • 2Department of Endocrinology, Hacettepe University School of Medicine, Ankara, Turkey
  • 3Department of Medical Oncology, Hacettepe University School of Medicine, Ankara, Turkey
Further Information

Publication History

Publication Date:
14 July 2009 (online)

Summary

We investigated whether erythrocyte aggregation (EA) is enhanced in type 2 diabetic patients who have developed microvascular or macrovascular complications. EA rates at high and low shear rates were analysed in 141 patients with type 2 diabetes who were further divided into 4 subgroups according to the status of diabetic complications and degree of metabolic control. Groups 1 (n = 43) and 2 (n = 23) consisted of well-controlled patients without and with clinically evident late complications, while groups 3 (n = 33) and 4 (n = 42) represented poorly controlled patients without and with these complications, respectively. 124 healthy subjects served as the control group. Mean EA rate was comparable between control subjects and group 1 both at high (2.05 ± 0.03 vs. 2.14 ± 0.07, respectively) and low (6.96 ± 0.02 vs. 7.04 ± 0.06, respectively) shear rates. Mean EA rate was also comparable between groups 2 and 4 at high (2.76 ± 0.09 vs. 2.94 ± 0.07, respectively) and low (8.18 ± 0.13 vs. 8.41 ±0.1, respectively) shear rates. However, EA at both shear rates in groups 2 and 4 were significantly higher than control subjects, group 1 (p < 0.0001) and group 3 (high shear rate EA: 2.76 ± 0.09 and low shear rate EA: 7.48 ± 0.07 (p < 0.01). In group 3, EA rates were significantly higher than control subjects and group 1 (p < 0.05) at both shear rates. No significant correlation was found between EA at high and low shear rates and fibrinogen levels in diabetic subgroups and control subjects. The data suggest that patients with type 2 diabetes who had developed clinically evident late complications have enhanced EA regardless of the degree of metabolic control. Whether enhanced EA is a primary phenomenon contributing to the development of these complications or it occurs secondary to their development remains to be clarified.

    >